Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.70 |
| ▸ | AR | P10275 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5925193 | 1.00 | PGR (0.70) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL3934258 | 0.88 | PGR (0.59) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL3934256 | 0.88 | PGR (0.59) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL11594373 | 0.88 | PGR (0.59) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL6845448 | 0.87 | CYP19A1 (0.62) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL6845447 | 0.87 | CYP19A1 (0.62) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL10390405 | 0.85 | MEN1 (0.64) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL11648870 | 0.84 | MEN1 (0.56) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL11648875 | 0.84 | MEN1 (0.56) | PGRCYP3A4NR3C1ARLMNA | |
| SCHEMBL4082888 | 0.84 | MEN1 (0.63) | PGRCYP3A4NR3C1ARLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | ELLIPSES PHARMA LTD (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-4192509-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | Ellipses Pharma Ltd (GB) | 2023-06-14 | — | — | EP | disclosed |
| US-20220409612-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20210060003-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2021-03-04 | — | — | US | disclosed |
| US-20200375978-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200093932-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| EP-3548028-A1 | TREATMENT OF CANCER | BlueLink Pharmaceuticals, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190070169-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LIMITED (GB) | 2019-03-07 | — | — | US | disclosed |
| EP-2477985-B1 | CRLX101 FOR USE IN THE TREATMENT OF CANCER | BLUELINK PHARMACEUTICALS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20060211873-A1 | Synthesis of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-21 | — | — | US | disclosed |
| CN-1255194-C | Pharmaceutical administration form | MUELLER D (DE) | 2006-05-10 | — | — | CN | disclosed |
| EP-1501858-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040024230-A1 | Synthesis of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2003092578-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
| EP-1359154-A1 | Further syntheses of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| CN-1224366-A | Pharmaceutical administration form | MUELLER D (DE) | 1999-07-28 | — | — | CN | disclosed |
| EP-0907388-A1 | PHARMACEUTICAL ADMINISTRATION FORM | Müller, Dieter (DE) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998000198-A1 | PHARMACEUTICAL ADMINISTRATION FORM | MUELLER DIETER (DE) | 1998-01-08 | — | — | WO | disclosed |
| US-3931167-A | Process for the manufacture of 3-keto-6-azido-4,6-bis-dehydro-steroids and intermediates useful therein | SCHERING CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024230-A1 | Synthesis of cyproterone acetate | CYP17A1, CYP19A1, CYP21A2 | PGR 78/4885CYP3A4 57/4885NR3C1 157/4885 |
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | PARP1, TOP1, PARP2 | PGR 1223/4885CYP3A4 1323/4885NR3C1 1089/4885 |
| US-20200375978-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | PGR 1684/4885CYP3A4 3103/4885NR3C1 2294/4885 |
| US-20200093932-A1 | TREATMENT OF CANCER | TDO2, IDO1, IDO2 | PGR 3100/4885CYP3A4 589/4885NR3C1 2812/4885 |
| US-20060211873-A1 | Synthesis of cyproterone acetate | CYP17A1, CYP19A1, HSD17B7 | PGR 77/4885CYP3A4 56/4885NR3C1 168/4885 |
| US-20190070169-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | PGR 1857/4885CYP3A4 4216/4885NR3C1 1935/4885 |
| US-20220409612-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | PGR 1857/4885CYP3A4 4216/4885NR3C1 1935/4885 |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PGR 2685/4885CYP3A4 4184/4885NR3C1 1395/4885 |
| US-20210060003-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | PGR 1857/4885CYP3A4 4216/4885NR3C1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.